Dambkowski Carl, chief medical officer at two companies, has filed 56 Form 4s with zero open-market purchases. His entire disclosed activity is on the sell side: roughly $19.6 million in sales across APGE and ORKA, with no buys and no acquisitions of shares through grants or exercises that would suggest fresh accumulation.
The recent pattern is heavily weighted toward APGE, the larger position. On June 22, 2026, he sold $3.5 million worth of APGE stock, the single largest transaction in the window. That was followed by smaller sales on July 1 ($730,070), August 5 ($737,935), and a $185,707.50 disposition on September 2 coded as a sale back to the issuer. Each of the three monthly sales was paired with an option exercise of $94,297.50, a mechanical step that typically precedes a sale of the underlying shares. The September 3 filings were four zero-value dispositions, likely transfers or cancellations.
ORKA activity is clustered in May and June. On May 21, 2026, he sold $793,661.92, $3,158,910.11, and $2,238,794.29, with three option exercises totaling roughly $494,804.55. Two more sales followed on June 11 ($1,572,200.60) and June 12 ($882,181.55). A June 2 grant of ORKA shares had zero value, meaning it was compensation, not a purchase. The last ORKA sale was June 12, and the last APGE sale was September 2. Across both tickers, the direction is uniform: sales, with no open-market buys in the entire filing history.
AI-assisted summary